Trial · NCT02783300
Outcomes66
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 66
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Part 1: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 30 months | All treated population included all participants who received at least one dose of GSK3326595. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 1: Number of Participants Withdrawn Due to AEs | Up to 30 months | All treated population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) | Up to 21 days | All treated population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 1: Number of Participants With Dose Modifications of GSK3326595 | Up to 30 months | All treated population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 1: Number of Participants With Worst Case Change From Baseline in Clinical Chemistry Parameters | Baseline (Day 1) and up to 30 months | All treated population. Only those participants with data available at specified categories have been analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 1: Number of Participants With Worst Case Change From Baseline in Hematology Parameters | Baseline (Day 1) and up to 30 months | All treated population. Only those participants with data available at specified categories have been analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 1: Number of Participants With Worst Case Change From Baseline in Coagulation Parameters | Baseline (Day 1) and up to 30 months | All treated population. Only those participants with data available at specified categories have been analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 1: Number of Participants With Worst Case Change From Baseline in Urinalysis Parameters | Baseline (Day 1) and up to 30 months | All treated population. Only those participants with data available at specified categories have been analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 1: Changes From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) and up to week 132 | All treated population. Only those participants with data available at specified timepoint have been analyzed. | Potential of Hydrogen (pH) | MEAN |
| PRIMARY | Part 1: Changes From Baseline in Urine Specific Gravity | Baseline (Day 1) and up to week 132 | All treated population. Only those participants with data available at specified timepoint have been analyzed. | Ratio | MEAN |
| PRIMARY | Part 1: Number of Participants With Maximum Grade Worst Case Increase Post-baseline Relative to Baseline in Vital Signs | Baseline (Day 1) and up to 30 months | All treated population. Only those participants with data available at specified categories have been analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 3: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 10 months | All treated population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 3: Number of Participants Withdrawn Due to AEs | Up to 10 months | All treated population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 3: Number of Participants With Dose Modifications of GSK3326595 and Pembrolizumab | Up to 10 months | All treated population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 3: Number of Participants With Worst Case Change From Baseline in Clinical Chemistry Parameters | Baseline (Day 1) and up to 10 months | All treated population. Only those participants with data available at specified categories have been analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 3: Number of Participants With Worst Case Change From Baseline in Hematology Parameters | Baseline (Day 1) and up to 10 months | All treated population. Only those participants with data available at specified categories have been analyzed. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 3: Number of Participants With Worst Case Change From Baseline in Coagulation Parameters | Baseline (Day 1) and up to 10 months | All treated population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 3: Number of Participants With Worst Case Change From Baseline in Urinalysis Parameters | Baseline (Day 1) and up to 10 months | All treated population | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Part 3: Changes From Baseline in Urine Potential of Hydrogen (pH) | Baseline (Day 1) and up to Week 42 | All treated population. Only those participants with data available at specified timepoint have been analyzed. | Potential of Hydrogen (pH) | MEAN |
| PRIMARY | Part 3: Changes From Baseline in Urine Specific Gravity | Baseline (Day 1) and up to Week 42 | All treated population. Only those participants with data available at specified timepoint have been analyzed. | Ratio | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02783300/outcomes